114 related articles for article (PubMed ID: 20486538)
21. Differential response to phytoestrogens in endocrine sensitive and resistant breast cancer cells in vitro.
Limer JL; Parkes AT; Speirs V
Int J Cancer; 2006 Aug; 119(3):515-21. PubMed ID: 16506217
[TBL] [Abstract][Full Text] [Related]
22. Isolated and combined action of tamoxifen and metformin in wild-type, tamoxifen-resistant, and estrogen-deprived MCF-7 cells.
Berstein LM; Yue W; Wang JP; Santen RJ
Breast Cancer Res Treat; 2011 Jul; 128(1):109-17. PubMed ID: 20683653
[TBL] [Abstract][Full Text] [Related]
23. Effect of vitamin E on tamoxifen-treated breast cancer cells.
Peralta EA; Viegas ML; Louis S; Engle DL; Dunnington GL
Surgery; 2006 Oct; 140(4):607-14; discussion 614-5. PubMed ID: 17011908
[TBL] [Abstract][Full Text] [Related]
24. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 1999 Jul; 18(29):4269-74. PubMed ID: 10435640
[TBL] [Abstract][Full Text] [Related]
25. [Cytotoxicity of tamoxifen and its principal metabolites in human breast cancer cell lines].
Bachmann-Moisson N; Barberi-Heyob M; Merlin JL; Ledrich ML; Batt AM; Guillemin F
Bull Cancer; 1996 Oct; 83(10):808-15. PubMed ID: 8952630
[TBL] [Abstract][Full Text] [Related]
26. Activation of estrogen receptor α by estradiol and cisplatin induces platinum-resistance in ovarian cancer cells.
Matsumura S; Ohta T; Yamanouchi K; Liu Z; Sudo T; Kojimahara T; Seino M; Narumi M; Tsutsumi S; Takahashi T; Takahashi K; Kurachi H; Nagase S
Cancer Biol Ther; 2017 Sep; 18(9):730-739. PubMed ID: 27689466
[TBL] [Abstract][Full Text] [Related]
27. Determinants of tamoxifen sensitivity control the nature of the synergistic interaction between tamoxifen and cisplatin.
McClay EF; Jones JA; Winski PJ; Albright KD; Christen RD; Howell SB
Cancer Res; 1996 Sep; 56(17):3993-7. PubMed ID: 8752169
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of MAP kinase promotes the recruitment of corepressor SMRT by tamoxifen-bound estrogen receptor alpha and potentiates tamoxifen action in MCF-7 cells.
Hong W; Chen L; Li J; Yao Z
Biochem Biophys Res Commun; 2010 May; 396(2):299-303. PubMed ID: 20406620
[TBL] [Abstract][Full Text] [Related]
29. Estrogen receptor alpha/beta isoforms, but not betacx, modulate unique patterns of gene expression and cell proliferation in Hs578T cells.
Secreto FJ; Monroe DG; Dutta S; Ingle JN; Spelsberg TC
J Cell Biochem; 2007 Aug; 101(5):1125-47. PubMed ID: 17520659
[TBL] [Abstract][Full Text] [Related]
30. Reversal of ER-β silencing by chromatin modifying agents overrides acquired tamoxifen resistance.
Pitta CA; Papageorgis P; Charalambous C; Constantinou AI
Cancer Lett; 2013 Sep; 337(2):167-76. PubMed ID: 23752064
[TBL] [Abstract][Full Text] [Related]
31. Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.
Zou A; Marschke KB; Arnold KE; Berger EM; Fitzgerald P; Mais DE; Allegretto EA
Mol Endocrinol; 1999 Mar; 13(3):418-30. PubMed ID: 10076999
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic utility of natural estrogen receptor beta agonists on ovarian cancer.
Liu J; Viswanadhapalli S; Garcia L; Zhou M; Nair BC; Kost E; Rao Tekmal R; Li R; Rao MK; Curiel T; Vadlamudi RK; Sareddy GR
Oncotarget; 2017 Jul; 8(30):50002-50014. PubMed ID: 28654894
[TBL] [Abstract][Full Text] [Related]
33. Raloxifene induces cell death and inhibits proliferation through multiple signaling pathways in prostate cancer cells expressing different levels of estrogen receptor α and β.
Rossi V; Bellastella G; De Rosa C; Abbondanza C; Visconti D; Maione L; Chieffi P; Della Ragione F; Prezioso D; De Bellis A; Bellastella A; Sinisi AA
J Cell Physiol; 2011 May; 226(5):1334-9. PubMed ID: 20945400
[TBL] [Abstract][Full Text] [Related]
34. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells.
Hutcheson IR; Knowlden JM; Madden TA; Barrow D; Gee JM; Wakeling AE; Nicholson RI
Breast Cancer Res Treat; 2003 Sep; 81(1):81-93. PubMed ID: 14531500
[TBL] [Abstract][Full Text] [Related]
35. Ligand-induced regulation of ERalpha and ERbeta is indicative of human breast cancer cell proliferation.
Power KA; Thompson LU
Breast Cancer Res Treat; 2003 Oct; 81(3):209-21. PubMed ID: 14620916
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen lowers the MMP-9/TIMP-1 ratio and inhibits the invasion capacity of ER-positive non-small cell lung cancer cells.
Wang XY; Wang Y; Liu HC
Biomed Pharmacother; 2011 Oct; 65(7):525-8. PubMed ID: 21993004
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen delays the development of resistance to cisplatin in human melanoma and ovarian cancer cell lines.
McClay EF; Albright KD; Jones JA; Christen RD; Howell SB
Br J Cancer; 1994 Sep; 70(3):449-52. PubMed ID: 8080729
[TBL] [Abstract][Full Text] [Related]
38. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P
Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292
[TBL] [Abstract][Full Text] [Related]
39. Bidirectional cross talk between ERalpha and EGFR signalling pathways regulates tamoxifen-resistant growth.
Britton DJ; Hutcheson IR; Knowlden JM; Barrow D; Giles M; McClelland RA; Gee JM; Nicholson RI
Breast Cancer Res Treat; 2006 Mar; 96(2):131-46. PubMed ID: 16261397
[TBL] [Abstract][Full Text] [Related]
40. Estrogen receptor beta exerts growth-inhibitory effects on human mammary epithelial cells.
Treeck O; Lattrich C; Springwald A; Ortmann O
Breast Cancer Res Treat; 2010 Apr; 120(3):557-65. PubMed ID: 19434490
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]